Cytosorbents Crp (CTSO) - Total Assets
Based on the latest financial reports, Cytosorbents Crp (CTSO) holds total assets worth $40.56 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Cytosorbents Crp cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Cytosorbents Crp - Total Assets Trend (2004–2025)
This chart illustrates how Cytosorbents Crp's total assets have evolved over time, based on quarterly financial data. Explore CTSO long-term investment intensity to see how much of total assets are deployed in long-term investments.
Cytosorbents Crp - Asset Composition Analysis
Current Asset Composition (December 2025)
Cytosorbents Crp's total assets of $40.56 Million consist of 46.7% current assets and 53.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.1% |
| Accounts Receivable | $7.55 Million | 17.1% |
| Inventory | $5.28 Million | 12.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.23 Million | 7.3% |
| Goodwill | $3.23 Million | 7.3% |
Asset Composition Trend (2004–2025)
This chart illustrates how Cytosorbents Crp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Cytosorbents Crp (CTSO) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cytosorbents Crp's current assets represent 46.7% of total assets in 2025, an increase from 33.3% in 2004.
- Cash Position: Cash and equivalents constituted 14.1% of total assets in 2025, down from 33.3% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 17.1% of total assets.
Cytosorbents Crp Competitors by Total Assets
Key competitors of Cytosorbents Crp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥912.83 Million |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.62 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
Cytosorbents Crp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.09 | 2.61 | 7.14 |
| Quick Ratio | 0.81 | 2.30 | 6.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.45 Million | $15.68 Million | $66.29 Million |
Cytosorbents Crp - Advanced Valuation Insights
This section examines the relationship between Cytosorbents Crp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.11 |
| Latest Market Cap to Assets Ratio | 0.57 |
| Asset Growth Rate (YoY) | -6.7% |
| Total Assets | $44.18 Million |
| Market Capitalization | $25.11 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cytosorbents Crp's assets below their book value (0.57x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Cytosorbents Crp's assets decreased by 6.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cytosorbents Crp (2004–2025)
The table below shows the annual total assets of Cytosorbents Crp from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $44.18 Million | -6.73% |
| 2024-12-31 | $47.37 Million | -11.06% |
| 2023-12-31 | $53.26 Million | -15.77% |
| 2022-12-31 | $63.23 Million | -29.37% |
| 2021-12-31 | $89.52 Million | -0.48% |
| 2020-12-31 | $89.95 Million | +228.49% |
| 2019-12-31 | $27.38 Million | -16.38% |
| 2018-12-31 | $32.75 Million | +35.86% |
| 2017-12-31 | $24.10 Million | +148.65% |
| 2016-12-31 | $9.69 Million | -13.87% |
| 2015-12-31 | $11.25 Million | +32.89% |
| 2014-12-31 | $8.47 Million | +109.33% |
| 2013-12-31 | $4.05 Million | +21.15% |
| 2012-12-31 | $3.34 Million | +57.33% |
| 2011-12-31 | $2.12 Million | +17.14% |
| 2010-12-31 | $1.81 Million | -19.06% |
| 2009-12-31 | $2.24 Million | -33.91% |
| 2008-12-31 | $3.39 Million | +322.04% |
| 2007-12-31 | $802.57K | -76.70% |
| 2006-12-31 | $3.45 Million | +17991.84% |
| 2005-12-31 | $19.04K | -36.53% |
| 2004-12-31 | $30.00K | -- |
About Cytosorbents Crp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and criti… Read more